Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women

Patients diagnosed with ductal carcinoma in situ (DCIS) at a young age appear to have a different natural history and biology, including a higher local relapse rate, than patients diagnosed later in life. The current study compared various pathologic and molecular features of DCIS arising in a cohort of young women with those of DCIS arising in a cohort of older women to identify potential biologic differences between these two populations of patients.

[1]  W. Gregory,et al.  The classification of ductal carcinoma in situ and its association with biological markers. , 1994, Seminars in diagnostic pathology.

[2]  D. Schultz,et al.  Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. , 2001, International journal of radiation oncology, biology, physics.

[3]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[4]  M. Indelli,et al.  Modulation of biomarkers in minimal breast carcinoma , 1998, Cancer.

[5]  L. Liberman,et al.  Long term follow‐up of women with ductal carcinoma in situ treated with breast‐conserving surgery , 1999, Cancer.

[6]  F. Vicini,et al.  Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast‐conserving therapy , 2000, Cancer.

[7]  I. Ellis,et al.  Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. , 1993, British Journal of Cancer.

[8]  J. Bártková,et al.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. , 1990, Human pathology.

[9]  J. Vilcoq,et al.  Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. , 1989, International journal of radiation oncology, biology, physics.

[10]  F. O'Malley,et al.  Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. , 1997, Human pathology.

[11]  V. Canzonieri,et al.  Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. , 1996, European journal of cancer.

[12]  I. Gage,et al.  Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast‐conserving therapy , 1996, Cancer.

[13]  K I Bland,et al.  Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53 , 2001, Annals of surgery.

[14]  B. McCormick,et al.  Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. , 1991, International journal of radiation oncology, biology, physics.

[15]  M. Fernö,et al.  Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. , 2001, European journal of cancer.

[16]  M. Fernö,et al.  Correlation between p53, c‐erbB‐2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node‐negative breast carcinomas: prognostic implications , 1999, The Journal of pathology.

[17]  F. Vicini,et al.  Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. Pelosi,et al.  Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis , 1997, International journal of cancer.

[19]  A. Patchefsky,et al.  Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). , 1997, International journal of radiation oncology, biology, physics.

[20]  L Duchateau,et al.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Schwartz,et al.  [The consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999]. , 2000, Bulletin du cancer.

[22]  Robert C. Frazier,et al.  Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Vicini,et al.  Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age , 2000, Cancer.

[24]  G. Schwartz,et al.  Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. , 2000, Cancer.

[25]  J. Rodriguez-Sierra,et al.  Younger women with breast carcinoma have a poorer prognosis than older women , 1996, Cancer.

[26]  S. Schnitt,et al.  The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy. , 1988, International journal of radiation oncology, biology, physics.

[27]  J Costantino,et al.  Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight‐year update of Protocol B‐17 , 1999, Cancer.

[28]  C. Howe,et al.  Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. , 2001, Experimental and molecular pathology.

[29]  L. Holmberg,et al.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness , 2001, British Journal of Cancer.

[30]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  I Persson,et al.  The relation between survival and age at diagnosis in breast cancer. , 1986, The New England journal of medicine.

[32]  F. Schmitt,et al.  Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c‐erbB‐2 protein , 1995, Cancer.

[33]  M. J. van de Vijver,et al.  Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. , 1998, International journal of radiation oncology, biology, physics.

[34]  B. Asselain,et al.  Age as prognostic factor in premenopausal breast carcinoma , 1993, The Lancet.

[35]  I. Christensen,et al.  Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy , 2000, Breast Cancer Research and Treatment.

[36]  D. Schultz,et al.  Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast‐conserving surgery and definitive irradiation correlation of pathologic parameters with outcome of treatment , 1993, Cancer.

[37]  James Dignam,et al.  Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial , 1999, The Lancet.

[38]  L Piana,et al.  Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features , 1995, International journal of cancer.

[39]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.